Factors affecting epirubicin pharmacokinetics and toxicity: Evidence against using body-surface area for dose calculation

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2299-2304

  Gurney, Howard P ^a   Ackland, Stephen ^b   Gebski, Val ^b   Farrell, Geoffrey ^b  

^a WESTMEAD HOSPITAL   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SIZE; BODY SURFACE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION FUNCTION; DOSE CALCULATION; DRUG BILE LEVEL; DRUG EFFICACY; FEMALE; HUMAN; LIVER FUNCTION; MALE; NEUTROPENIA; PATIENT CODING; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STEADY STATE;

EID: 0031860380     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2299     Document Type: Article

References (19)

1. Pinkel D: The use of body surface area as a criterion of drug dosage in cancer chemotherapy. Cancer Res 18:853-856, 1958
2. Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 14:2590-2611, 1996
3. Grochow LB, Baraldi C, Noe D: Is dose normalization to weight or body surface area useful in adults? J Natl Cancer Inst 82:323-325, 1990
4. Reilly JJ, Workman P: Normalisation of anti-cancer drug dosage using body weight and surface area: Is it worthwhile? A review of theoretical and practical considerations. Cancer Chemother Pharmacol 32:411-418, 1993
5. Smith HW: The Kidney, Structure and Function in Health and Disease. New York, Oxford University, 1951
6. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
7. Robert J: Clinical pharmacokinetics of epirubicin. Clin Pharmacokinet 26:428-438, 1994
8. Twelves CJ, Dobbs NA, Michael Y, et al: Clinical pharmacokinetics of epirubicin: The importance of liver biochemistry tests. Br J Cancer 66:765-769, 1992
9. Camaggi CM, Strocchi E, Comparsi R, et al: Biliary excretion and pharmacokinetics of 4′ epidoxorubicin (epirubicin) in advanced cancer patients. Cancer Chemother Pharmacol 18:47-50, 1986
10. Du Bois D, Du Bois EF: A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 17:863-871, 1916
11. Farrell GC, Zaluzuy L: Accuracy and clinical utility of modified tests of antipyrine metabolism. Br J Clin Pharmacol 18:559-565, 1984
12. Camaggi CM, Comparsi R, Strocchi E, et al: HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids. Cancer Chemother Pharmacol 21:216-220, 1988
13. Robert J, Bui NB: Pharmacokinetics and metabolism of epirubicin administered as IV bolus and 48-hr infusion in patients with advanced soft-tissue sarcoma. Ann Oncol 3:651-656, 1992
14. Dobbs NA, Twelves CJ, Rizzi P, et al: Epirubicin in hepatocellular carcinoma: Pharmacokinetics and clinical activity. Cancer Chemother Pharmacol 34:405-410, 1994
15. Engel G, Heidemann HU, Cosme J, et al: Antipyrine as a probe for human oxidative drug metabolism: Identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation. Clin Pharmacol Ther 59:613-623, 1996
16. Goeptar AR, Groot EJ, Scheerens H, et al: Cytotoxicity of mitomycin C and Adriamycin in freshly isolated rat hepatocytes: The role of cytochrome P450. Cancer Res 54:2411-2418, 1994
17. Preiss R, Matthias M, Sohr R: Pharmacokinetics of Adriamycin, Adriamycinol, and antipyrine in patients with moderate tumor involvement of the liver. J Cancer Res Clin Oncol 113:593-598, 1987
18. Erlinger S: Drug-induced cholestasis. J Hepatol 26:1-4, 1997 (suppl 1)
19. McIntyre N, Rosalki S: Biochemical investigations in the management of liver disease, in McIntyre N, Benhamou J, Bircher J, et al (eds): Oxford Textbook of Clinical Hepatology. Oxford, United Kingdom, Oxford University, 1991, pp 293-309